The main thrust of the RTS is as following: The idea behind all of this to provide a secure environment for payment processing and preventing financial fraud and theft. Establishing national/regional/international standards is one way of preventing or overcoming this problem. Payment transaction history of each PSP’s end user. This TPP interface should have the same functionality and deliver the same level of support as for customers transacting directly with their bank. and provide the high level of security which is necessary for financial transactions. have the responsibility to consider the available standards, specify the correct one, enforce compliance, and use the item correctly. Care must be taken to ensure that active pharmaceutical compounds remain stable and unaffected by packaging materials or storage conditions. A technical standard may be developed privately or unilaterally, for example by a corporation, regulatory body, military, etc. For trusted beneficiaries defined by the payer. 0
It’s worth highlighting the latest practical exemptions for applying SCA: Under PSD2, third party providers (TPPs) will be granted consented access to customer information through the banks’ infrastructure to deliver new value-added services. The elements required to ensure strong customer authenticationare defined as follows in the RTS: 1. These elements are defined in detail in, Annexure III and IV of the eIDAS regulation. In short, we could say that PSD2 covers the “what” aspect of the regulation whereas the RTS defines the “how.” Here, you'll find a whistle-stop tour of a few key headlines from the RTS. Toxicology Preclinical Drug and Medical Device Development Regulatory Affairs. In social sciences, including economics, a standard is useful if it is a solution to a coordination problem: Inherence- Something that the user is These elements must be independent of each other so as to mitigate the risk of fraud if one of them is compromised. This ensures that transactions are treated appropriately based on the level of risk. Standards organizations often have more diverse input and usually develop voluntary standards: these might become mandatory if adopted by a government (i.e., through legislation), business contract, etc. It could be about making a product, managing a process, delivering a service or supplying materials – standards cover a huge range of activities. The standards make reference to the PSD2 directive as well as other mechanisms for ensuring transactional security like eIDAS and trust services. 1025, 2020, Annex 4, WHO Technical Report Series 929, 2005, Annex 5, WHO Technical Report Series 929, 2005, Annex 9, WHO Technical Report Series 902, 2002, Annex 11, WHO Technical Report Series 1010, 2018, Annex 6, WHO Technical Report Series 1019, 2019, Coronavirus disease outbreak (COVID-2019), Coronavirus disease outbreak (COVID-19) », Guidance on good data and record management practices, Stability Testing of Pharmaceutical Products in a Global Environment, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, WHO guidelines on Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability (revision), WHO âBiowaiver Listâ: proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms, Protocol to conduct equilibrium solubility experiments for the purpose of Biopharmaceutics Classification System-based classification of active pharmaceutical ingredients for biowaiver, Guidance for organizations performing in vivo bioequivalence studies (revision), General background notes and list of international comparator pharmaceutical products, Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products, List of International Comparator products (September 2016), Procedure for prequalification of pharmaceutical products, Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities, WHO guidelines on variations to a prequalified product, Collaborative procedure between the World Health Organization (WHO) prequalification team and national medicines regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines (revision), Guidelines on submission of documentation for a multisource (generic) finished pharmaceutical product for the WHO Prequalification of Medicines Programme: quality part, Guidelines on submission of documentation for prequalification of innovator finished pharmaceutical products approved by stringent regulatory authorities, Prequalification of quality control laboratories.